Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy
<b>Background:</b> Muscle wasting, also known as myopenia, is frequent in rheumatoid arthritis (RA). To date, it is still unknown if the failure of pharmacologic therapies increases the risk of myopenia in RA. <b>Objective:</b> To identify if treatment failure with convention...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-10-01
|
| Series: | Healthcare |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9032/10/10/2004 |
| _version_ | 1797473066516742144 |
|---|---|
| author | Eli E. Gomez-Ramirez Melissa Ramirez-Villafaña Jorge I. Gamez-Nava Fidencio Cons-Molina Norma A. Rodriguez Jimenez Ana M. Saldaña-Cruz Ernesto G. Cardona-Muñoz Sylvia E. Totsuka-Sutto Juan M. Ponce-Guarneros Xochitl Trujillo Miguel Huerta Alfonso J. Cruz-Jentoft Laura Gonzalez-Lopez |
| author_facet | Eli E. Gomez-Ramirez Melissa Ramirez-Villafaña Jorge I. Gamez-Nava Fidencio Cons-Molina Norma A. Rodriguez Jimenez Ana M. Saldaña-Cruz Ernesto G. Cardona-Muñoz Sylvia E. Totsuka-Sutto Juan M. Ponce-Guarneros Xochitl Trujillo Miguel Huerta Alfonso J. Cruz-Jentoft Laura Gonzalez-Lopez |
| author_sort | Eli E. Gomez-Ramirez |
| collection | DOAJ |
| description | <b>Background:</b> Muscle wasting, also known as myopenia, is frequent in rheumatoid arthritis (RA). To date, it is still unknown if the failure of pharmacologic therapies increases the risk of myopenia in RA. <b>Objective:</b> To identify if treatment failure with conventional synthetic DMARDs (csDMARDs) constitutes an independent risk factor of muscle wasting in women with RA. <b>Methods:</b> This was a cross-sectional study. We included 277 women with RA. Assessments in RA patients included: clinical, epidemiological, and therapeutic variables. The skeletal muscle index (SMI) was estimated by DXA, and myopenia was diagnosed if they had an SMI < 5.45 kg/m<sup>2</sup>. Multivariable logistic regression models identified risk factors of myopenia. <b>Results:</b> Muscle wasting was observed in 28.2% of patients with RA. The risk factors of myopenia in RA were menopausal (OR: 4.45, 95% CI: 1.86 to 10.64) and failure of combined therapy with csDMARDs (OR: 2.42, 95% CI: 1.15 to 5.07). The increased body mass index was protective (OR:0.81, 95% CI: 0.75 to 0.87). <b>Conclusions:</b> Around one of four patients with RA presented muscle wasting. Muscle wasting is related to treatment failure of combined csDMARDs; other factors influencing the presence of muscle wasting is being postmenopausal, whereas, the body mass index was a protective factor. |
| first_indexed | 2024-03-09T20:09:52Z |
| format | Article |
| id | doaj.art-9065f187a52d46af85d00073d9333586 |
| institution | Directory Open Access Journal |
| issn | 2227-9032 |
| language | English |
| last_indexed | 2024-03-09T20:09:52Z |
| publishDate | 2022-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Healthcare |
| spelling | doaj.art-9065f187a52d46af85d00073d93335862023-11-24T00:20:44ZengMDPI AGHealthcare2227-90322022-10-011010200410.3390/healthcare10102004Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination TherapyEli E. Gomez-Ramirez0Melissa Ramirez-Villafaña1Jorge I. Gamez-Nava2Fidencio Cons-Molina3Norma A. Rodriguez Jimenez4Ana M. Saldaña-Cruz5Ernesto G. Cardona-Muñoz6Sylvia E. Totsuka-Sutto7Juan M. Ponce-Guarneros8Xochitl Trujillo9Miguel Huerta10Alfonso J. Cruz-Jentoft11Laura Gonzalez-Lopez12Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, MexicoResearch Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Guadalajara 44340, MexicoDoctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, MexicoCentro de Investigación de Artritis y Osteoporosis, Mexicali 21200, MexicoResearch Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Guadalajara 44340, MexicoResearch Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Guadalajara 44340, MexicoResearch Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Guadalajara 44340, MexicoResearch Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Guadalajara 44340, MexicoResearch Group for the Assessment of Prognosis Biomarkers in Autoimmune Disorders, Guadalajara 44340, MexicoCentro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima 28040, MexicoCentro Universitario de Investigaciones Biomédicas (CUIB), Universidad de Colima, Colima 28040, MexicoServicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), 28034 Madrid, SpainDoctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Mexico<b>Background:</b> Muscle wasting, also known as myopenia, is frequent in rheumatoid arthritis (RA). To date, it is still unknown if the failure of pharmacologic therapies increases the risk of myopenia in RA. <b>Objective:</b> To identify if treatment failure with conventional synthetic DMARDs (csDMARDs) constitutes an independent risk factor of muscle wasting in women with RA. <b>Methods:</b> This was a cross-sectional study. We included 277 women with RA. Assessments in RA patients included: clinical, epidemiological, and therapeutic variables. The skeletal muscle index (SMI) was estimated by DXA, and myopenia was diagnosed if they had an SMI < 5.45 kg/m<sup>2</sup>. Multivariable logistic regression models identified risk factors of myopenia. <b>Results:</b> Muscle wasting was observed in 28.2% of patients with RA. The risk factors of myopenia in RA were menopausal (OR: 4.45, 95% CI: 1.86 to 10.64) and failure of combined therapy with csDMARDs (OR: 2.42, 95% CI: 1.15 to 5.07). The increased body mass index was protective (OR:0.81, 95% CI: 0.75 to 0.87). <b>Conclusions:</b> Around one of four patients with RA presented muscle wasting. Muscle wasting is related to treatment failure of combined csDMARDs; other factors influencing the presence of muscle wasting is being postmenopausal, whereas, the body mass index was a protective factor.https://www.mdpi.com/2227-9032/10/10/2004rheumatoid arthritismuscle wastingmyopeniatherapy failurecsDMARDs |
| spellingShingle | Eli E. Gomez-Ramirez Melissa Ramirez-Villafaña Jorge I. Gamez-Nava Fidencio Cons-Molina Norma A. Rodriguez Jimenez Ana M. Saldaña-Cruz Ernesto G. Cardona-Muñoz Sylvia E. Totsuka-Sutto Juan M. Ponce-Guarneros Xochitl Trujillo Miguel Huerta Alfonso J. Cruz-Jentoft Laura Gonzalez-Lopez Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy Healthcare rheumatoid arthritis muscle wasting myopenia therapy failure csDMARDs |
| title | Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy |
| title_full | Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy |
| title_fullStr | Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy |
| title_full_unstemmed | Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy |
| title_short | Risk Factors of Muscle Wasting in Women with Rheumatoid Arthritis: Relevance of the Persistent Failure of Conventional Combination Therapy |
| title_sort | risk factors of muscle wasting in women with rheumatoid arthritis relevance of the persistent failure of conventional combination therapy |
| topic | rheumatoid arthritis muscle wasting myopenia therapy failure csDMARDs |
| url | https://www.mdpi.com/2227-9032/10/10/2004 |
| work_keys_str_mv | AT eliegomezramirez riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT melissaramirezvillafana riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT jorgeigameznava riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT fidencioconsmolina riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT normaarodriguezjimenez riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT anamsaldanacruz riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT ernestogcardonamunoz riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT sylviaetotsukasutto riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT juanmponceguarneros riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT xochitltrujillo riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT miguelhuerta riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT alfonsojcruzjentoft riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy AT lauragonzalezlopez riskfactorsofmusclewastinginwomenwithrheumatoidarthritisrelevanceofthepersistentfailureofconventionalcombinationtherapy |